Piperacillin and gentamicin v carbenicillin and gentamicin for treatment of serious gram-negative infections.
Piperacillin sodium, a new penicillin with remarkable in vitro activity against Pseudomonas aeruginosa and other Gram-negative bacilli, and gentamicin sulfate were compared with carbenicillin disodium and gentamicin in a prospective, randomized, double-blind comparison for treating serious Gram-negative infections. Of the 32 patients whose courses were "evaluable" for efficacy, 12 of 14 who received piperacillin and gentamicin and 13 of 18 who received carbenicillin and gentamicin had favorable outcomes. Of the 99 patients whose courses were evaluable for toxicity, nine of 51 recipients of piperacillin and gentamicin and 15 of 48 recipients of carbenicillin and gentamicin suffered clinical reactions possibly, probably, or definitely related to the penicillin. No statistically significant differences were found in the two groups in the frequencies of biochemical abnormalities, including hypokalemia, that occurred in 19 or 44 recipients of piperacillin and gentamicin and 16 of 45 recipients of carbenicillin and gentamicin. Thus, this study did not prove differences in efficacy of toxicity for piperacillin and gentamicin plus carbenicillin and gentamicin for serious Gram-negative infections.
D001424:Bacterial Infections / Q000188:drug therapy*; D002228:Carbenicillin / Q000008:administration & dosage* / Q000009:adverse effects; D004359:Drug Therapy, Combination; D005839:Gentamicins / Q000008:administration & dosage* / Q000009:adverse effects; D006088:Gram-Negative Aerobic Bacteria; D006801:Humans; D010406:Penicillins / Q000008:administration & dosage* / Q000009:adverse effects; D010878:Piperacillin
D005839:Gentamicins; D010406:Penicillins; D002228:Carbenicillin; D010878:Piperacillin